Parkinson's disease; modern treatment.
D000547:Amantadine / Q000627:therapeutic use; D000661:Amphetamine / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000627:therapeutic use; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D065098:Catechol O-Methyltransferase Inhibitors; D003891:Desipramine / Q000627:therapeutic use; D004295:Dihydroxyphenylalanine / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D004344:Drug Incompatibility; D004357:Drug Synergism; D006801:Humans; D007099:Imipramine / Q000627:therapeutic use; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D010276:Parasympatholytics / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy*
D000928:Antidepressive Agents; D000978:Antiparkinson Agents; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D065098:Catechol O-Methyltransferase Inhibitors; D004338:Drug Combinations; D008996:Monoamine Oxidase Inhibitors; D010276:Parasympatholytics; D004295:Dihydroxyphenylalanine; D000547:Amantadine; D000661:Amphetamine; D007099:Imipramine; D003891:Desipramine